Travere Therapeutics, Inc. (TVTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$59.00−$1.62 (−2.67%) on the dayAs of the close; data may be delayed.
TVTX price, last 12 months
Key stats
- Previous close
- $60.62
- Open
- $60.70
- Day range
- $59.00 – $60.89
- 52-week range
- $22.06 – $68.73
- Volume
- 1M
- Avg volume (20 days)
- 1.5M
- Market cap
- $5.6B
Performance
1W−6.0%
1M−12.1%
3M+0.3%
6M+111.3%
YTD+54.4%
1Y+141.7%
vs S&P 500, 1Y+124.9 pts
Technicals and fundamentals
About Travere Therapeutics, Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $5.6B